A new enhancer element of hepatitis B virus HBV, ENII, located in the X gene coding region and upstream of the C promoter, has been identffied. As determined by deletion analysis, the sequence around nucleotides 1627 to 1732 was suggested to be essential for ENII activity. ENII was cell type specific. It showed high activity in HepG2 cells but no detectable activity in CV-1 cells. A protein-binding site was identified by footprinting in nucleotides 1648 to 1671. The minimum sequence and function of ENHI are under investigation.
Hepatitis B is a serious worldwide viral disease caused by hepatitis B virus (HBV). Chronic infection by HBV is closely related to the development of hepatocellular carcinoma. Although HBV vaccine has been proven to be useful in protecting from HBV infection, there are no efficient therapeutic measures for the control of HBV. Study of the expression and regulation of HBV genes is one of the most important approaches in looking for new breakthroughs.
HBV has a double-stranded DNA genome with a partially single stranded region that codes for surface antigen (S gene), core antigen (C gene), X protein (X gene), and viral polymerase (P gene) (10) . Four promoters have been identified in HBV: promoters of the S gene, SPI and SPII (7), C promoter (4, 5) , and X promoter (12) . An enhancer has also been identified in HBV (6, 11) , which is capable of stimulating the transcriptional function of HBV promoters. Another enhancer element associated with the glucocorticoid receptor-binding site was shown to be present in the S gene coding region (13) . The X gene product also positively regulates various promoters, but in a trans-acting manner (8, 17) . Investigation of the regulatory elements and their biological function is crucial to an understanding of viral gene expression.
We report here our results on the identification of a new enhancer element, ENII, which is located in the X gene coding region and upstream of the C promoter.
Plasmid pADR-1 contains a complete genome of HBV subtype adr (15) , which has a unique BamHI site downstream of the S gene. The HBV genome cloned in pADR-1 is 3,215 base pairs (bp) in size and has been completely sequenced (1) . By cleavage at the BstEII site upstream of the pre-Sl region of the S gene followed by insertion of a BamHI linker, a new BamHI site was introduced in place of the BstEII site. The resulting plasmid, pADR-2B, has two BamHI sites. HBV DNA of pADR-2B was divided into two parts by BamHI digestion. One fragment of 1.8 kilobase pairs (kb) contains the pre-S1-pre-2-S coding sequence, the SPII promoter, the glucocorticoid receptor-binding element site, and the previously mapped enhancer element; the second fragment of 1.4 kb contains the X gene, the C gene, and the upstream sequence of pre-S. These two fragments were inserted into plasmid pAlOCAT (Fig. 1 (Fig. 3 ). These three fragments were inserted into the BamHI site of pAlOCAT, producing pAlOCATBxl, pAlOCATBc, and pAlOCATBr, respectively. Upon transfection of HepG2 cells, only pAlOCATBxl, which contains the 584-bp BamHI-BglII fragment, could stimulate SV40 promoter and enhanced CAT activity (Fig. 4) . Furthermore, the stimulatory activity was similar when this fragment was inserted into the BglII site of pAlOCAT upstream of the SV40 early promoter in different orientations, as shown in Fig. 4 for pA10CATBx2 and pA10CATBx3. As mentioned, the BamHI-BgiII (1403 to 1987) fragment includes most of the X protein region. However, involvement of the X protein residues as transacting factors in enhancing CAT activity was unlikely since the constructs lacked the X promoter and the first ATG and termination codons of the X, C, and P genes are indicated, as are the important restriction sites. The BstII site has been changed to BamHI as described in the legend to Fig. 1 . All of the nucleotide numbers given in this report were assigned by taking the first nucleotide of the mutated recognition sequence of EcoRI as nt 1, since there is no EcoRI site within HBV DNA of pADR-1 (1, 14) .
cells simultaneously. The new enhancer element, ENII, in these three plasmids enhanced CAT gene expression in HepG2 cells (Fig. 4) but not in CV-1 cells (Fig. 5) the synthesis of a truncated X gene product, a cotransfection experiment was performed. The BamHI-StuI (1403 to 2024) fragment and a shorter fragment (1627 to 1879) were cloned into vector Bluescribe (Genefit product), and the resulting plasmids BlueBx and BlueBx23A were cotransfected with pAlOCAT. No significant CAT activity was observed ( Table  1) .
The trans-regulating factors that may be required for the function of the new enhancer were also studied. Nuclear extracts from HepG2 cells were prepared. Band shift and competition assay were performed, using the BamHI-BglII fragment (1403 to 1987) and a shorter fragment BamHI- HincII (1403 to 1685). The results revealed the presence of a sequence-specific binding protein in the nuclear extracts that bound to the sequence where the new enhancer element is located. DNase I footprinting analysis showed the binding site of this protein factor to be located in nt 1648 to 1671 of HBV DNA (Fig. 7) . This binding activity was also found in extracts from Hep3B and rat liver cells but not in extracts from HeLa cells when the same concentration of extracts was used (data not shown). A similar protein-binding site had also been found by Karpen et al. (5) and was previously considered to be the core promoter element. However, the core promoter, as identified by Honigwachs et al. (4) 1774) was end labeled at the RsaI site and incubated in the presence of 5 ,ug of poly(dI-dC) with nuclear extract of HepG2. As indicated above the lanes, 0, 2, 4, or 6 ,ug of HepG2 nuclear extract was added. A DNase I concentration of 3 j,g/ml was used in each case. Lane G, Sequence ladder. The protein-binding sequence is indicated, and the palindromic sequence is marked by arrows.
promoters and how it interacts with other regulatory elements in HBV genome are now under investigation. 
